^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Istodax (romidepsin) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1356 Histone Deacetylase Inhibition Restores Therapy Response in TP53mutated Acute Lymphoblastic Leukemia to Chemotherapy
Published date:
11/03/2022
Excerpt:
...preliminary mouse experiments using TP53 deleted RCH-ACV cells showed that romidepsin improves the response to cytarabine in TP53 aberrant leukemia in vivo...Romidepsin can restore response to therapy in TP53 deleted ALL, presumably by reactivation of p53 target genes in response to cellular stress. Therefore, romidepsin may be used to improve therapy response in relapsed TP53 deleted ALL.
DOI:
https://doi.org/10.1182/blood-2022-157118
